Does SELPERCATINIB Cause Therapy partial responder? 10 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 10 reports of Therapy partial responder have been filed in association with SELPERCATINIB (RETEVMO). This represents 0.9% of all adverse event reports for SELPERCATINIB.
10
Reports of Therapy partial responder with SELPERCATINIB
0.9%
of all SELPERCATINIB reports
1
Deaths
1
Hospitalizations
How Dangerous Is Therapy partial responder From SELPERCATINIB?
Of the 10 reports, 1 (10.0%) resulted in death, 1 (10.0%) required hospitalization.
Is Therapy partial responder Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for SELPERCATINIB. However, 10 reports have been filed with the FAERS database.
What Other Side Effects Does SELPERCATINIB Cause?
Malignant neoplasm progression (106)
Death (90)
Hypertension (58)
Hypersensitivity (55)
Diarrhoea (54)
Fatigue (51)
Rash (49)
Hepatic function abnormal (42)
Alanine aminotransferase increased (38)
Pyrexia (38)
What Other Drugs Cause Therapy partial responder?
CYCLOPHOSPHAMIDE (1,397)
RITUXIMAB (1,219)
DEXAMETHASONE (1,199)
PREDNISONE (1,176)
PEMBROLIZUMAB (1,125)
CARBOPLATIN (1,096)
DOXORUBICIN (834)
METHOTREXATE (775)
VINCRISTINE (707)
ETOPOSIDE (670)
Which SELPERCATINIB Alternatives Have Lower Therapy partial responder Risk?
SELPERCATINIB vs SELUMETINIB
SELPERCATINIB vs SEMAGLUTIDE
SELPERCATINIB vs SEMUSTINE
SELPERCATINIB vs SENNA LEAF
SELPERCATINIB vs SENNA LEAF\SENNOSIDES\SENNOSIDES A AND B